1. Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK -rearranged non-small cell lung cancer.
- Author
-
Zugazagoitia J, Biosca M, Oliveira J, Olmedo ME, Dómine M, Nadal E, Ruffinelli JC, Muñoz N, Luna AM, Hernández B, Martínez M, Gallego I, Martínez de Castro E, Font C, Calvo V, Martínez-Marín V, Corral J, Noguerón E, Mondéjar R, García Escobar I, Salvador-Coloma C, Juan Ó, Sánchez Cánovas M, Valdivia J, Ochoa MP, López Castro R, Obispo B, Pangua C, Sereno M, Fernández Franco L, Mielgo X, Calzas J, Blasco A, Aparisi F, Chara L, Grau JF, Soares M, Gómez A, Zenzola V, García-Morillo M, Cacho D, Díaz-Serrano A, Aguado C, Ponce-Aix S, González-Larriba JL, Muñoz AJ, Lora D, Paz-Ares L, and Manzano A
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung mortality, Carcinoma, Non-Small-Cell Lung pathology, Female, Gene Rearrangement, Humans, Incidence, Lung Neoplasms mortality, Lung Neoplasms pathology, Male, Middle Aged, Portugal epidemiology, Prognosis, Receptor Protein-Tyrosine Kinases genetics, Retrospective Studies, Spain epidemiology, Survival Analysis, Thromboembolism genetics, Young Adult, Anaplastic Lymphoma Kinase genetics, Carcinoma, Non-Small-Cell Lung genetics, Lung Neoplasms genetics, Thromboembolism epidemiology
- Abstract
Competing Interests: Conflict of interest: M. Biosca has received personal fees from Leo-Pharma and Sanofi, outside the submitted work. Conflict of interest: L. Paz-Ares has received honoraria from Roche, Lilly, Bristol Meyers Squibb, Merck & Sharp D., Boehringer Ing., Pfizer, AstraZeneca, Amgem and Novartis, outside the submitted work. Conflict of interest: A. Manzano has received personal fees from Pharmamar, Roche and AstraZeneca, outside the submitted work.
- Published
- 2018
- Full Text
- View/download PDF